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ABSTRACT: Current optimum medical treatments have had
limited success in the primary prevention of cardiovascular
events, underscoring the need for new pharmaceutical targets
and enhanced understanding of mechanistic metabolic dysregu-
lation. Here, we use a combination of novel metabolic proﬁling
methodologies, based on ultra-performance liquid chromatog-
raphy coupled to mass spectrometry (UPLC−MS) followed by
chemometric modeling, data integration, and pathway mapping,
to create a systems-level metabolic atlas of atherogenesis. We
apply this workﬂow to compare arterial tissue incorporating
plaque lesions to intimal thickening tissue (immediate preplaque
stage). We ﬁnd changes in several metabolite species consistent with well-established pathways in atherosclerosis, such as the
cholesterol, purine, pyrimidine, and ceramide pathways. We then illustrate diﬀerential levels of previously unassociated lipids to
atherogenesis, namely, phosphatidylethanolamine-ceramides (t-test p-values: 3.8 × 10−6 to 9.8 × 10−12). Most importantly, these
molecules appear to be interfacing two pathways recognized for their involvement in atherosclerosis: ceramide and cholesterol.
Furthermore, we show that β-oxidation intermediates (i.e., acylcarnitines) manifest a pattern indicating truncation of the process and
overall dysregulation of fatty acid metabolism and mitochondrial dysfunction. We develop a metabolic framework that oﬀers the
ability to map signiﬁcant statistical associations between detected biomarkers. These dysregulated molecules and consequent pathway
modulations may provide novel targets for pharmacotherapeutic intervention.
KEYWORDS: Atherosclerosis, atherogenesis, metabolic proﬁling, metabonomics, metabolomics, lipidomics, phenotyping, ceramide,
phospatidylethanolamine-ceramide, acylcarnitine
■ INTRODUCTION
According to estimates by the World Health Organization, ath-
erosclerosis is the number one cause of death in the western
world. Most adverse health events associated with atherosclerosis
are due to ﬂow limitation because of stenosing plaque or distal
embolization due to plaque rupture. Additionally, existing medi-
cal management strategies have had limited success in primary
prevention, and the scientiﬁc community is still struggling to ﬁnd
appropriate doses, drug regimens, and mechanisms of action.1,2
Atherosclerosis is a multicentric, multistage, and systemic
disease.3 Cell populations such as vascular smooth muscle cells
and leukocytes are known to be important in the manifestation of
the disease. These cells participate in microenvironmental interac-
tions in the arterial wall. Intraplaque composition and structure
can also be heterogeneous and subject to variation.4 In order to
understand the role of the microenvironment in the etiopatho-
genesis and progression of the disease, as well as the risk posed by
plaque destabilization, there is a need to understand biochemical
mechanisms leading to plaque accumulation and instability within
the context of a holistic framework. Current omics applications can
provide such a holistic representation on a systems level while, at the
same time, functioning as hypothesis-generating tools. Metabolic
proﬁling − also referred to as metabonomics or metabolomics,
depending on the purpose of the application− is a promising omics
strategy for elucidation of pathological mechanisms.5,6
Applications of metabolic proﬁling in cardiovascular disease
has been predominately initiated in pilot/feasibility studies7 and
using recognized animal models.8 Intervention studies conducted
using metabolic proﬁling tools and relating to atherosclerosis are
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also reported in the literature.9,10 Multicenter, large popula-
tion studies followed, aiming toward the identiﬁcation of rele-
vant risk factors.11−13 Currently, in the literature, only a limited
number of studies on cardiovascular disease apply meta-
bolic proﬁling technologies on human tissue14 or, speciﬁcally,
atherosclerosis.15 This dictates the need to emphasize top-
down systems biology applications that can provide important
biological, mechanistic, and systemic information at the tissue
level.
In this study, we adopted a metabolic proﬁling and molecular
biomarker discovery approach combined with computational
modeling to study the metabolic changes of the progression from
intimal thickening (INT) to stenosing plaque formation from
human carotid (CAR) and femoral (FEM) endarterectomy
specimens. It is important to address the diﬀerences in
metabotypes between these two diﬀerent anatomical locations
in the peripheral arterial tree, as they experience diﬀerences in
biochemical composition and rupture risk.16−18 Lastly, the use of
INT tissue as a control holds several advantages as opposed to
the use of normal tissue, including the following: (i) INT, rather
than normal tissue, is detected at plaque-prone sites from the
early years of a person’s life, (ii) it is the immediate stage prior to
progression to the lipid-laden stenosing plaque and thus the
experimental model can provide a more realistic course of the
disease, (iii) normal fresh tissue is diﬃcult to obtain for ethical
reasons, and (iv) arterial tissue considered to be normal may
contain subclinical and/or macroscopically undetectable disease.
To our knowledge, a metabolic proﬁling characterization of
plaques using INT tissue as a control has not been previously
reported.
We used ultra-performance liquid chromatography coupled
to mass spectrometry (UPLC−MS) in order to identify
dysregulated metabolites between the patient groups. Two
untargeted UPLC−MS methodologies were applied in order
to cover molecules spanning a wide range of physicochemical
properties. Highly predictive and cross-validated multivariate
statistical models demonstrated commonly dysregulated
metabolites from the FEM and CAR when they were
individually compared to INT. Moreover, we identify a global
metabolic phenotype (metabotype: the multiparametric
metabolic responses characterizing a phenotype)19 of plaque
formation, comprising metabolites known to be associated
with atherogenesis and, importantly, metabolites indicating
the contribution of biological pathways as yet unrecognized
for their involvement in atherogenesis. Finally, we developed a
framework for mapping signiﬁcant statistical interactions
between metabolites and biological pathways in relation to
atherogenesis.
■ MATERIAL AND METHODS
Patients
Research ethics committee approval (RREC 2989 and RREC
3199) and informed consent were obtained for the collection of
endarterectomy specimens. Retrieved samples were stored at
−80 °C until the time of dissection and metabolite extraction.
The atherosclerotic plaque (> 50% stenosis) tissue samples used
in this study were obtained from a total of 78 patients from the
Academic Section of Vascular Surgery, Imperial College London:
52 patients underwent carotid endarterectomy (CAR) and 26
patients underwent femoral endarterectomy (FEM). From a
proportion of these samples, areas of intimal thickening (INT)
were separated from the stenosing plaque segment (9 samples
from carotid and 7 samples from femoral tissue). INT tissue,
found at the proximal and distal extents of stenosing atheroma
samples, served as control tissue in this study. Patients’ clinical
characteristics are detailed in Table 1.
Tissue Dissection and Metabolite Extraction
Parts of plaque tissue, and intima tissue adjacent to plaque, were
dissected, and sections were harvested for metabolite extraction.
Tissue section weights were in the range of 153−416 mg.
Tissue samples were loaded into appropriate bead-beating tubes
(Percellys Steel-Kit, Germany) along with steel beads and
subjected to tissue lysis and metabolite extraction. A consecutive
extraction protocol was applied with aqueous extraction followed
by organic as previously described (Vorkas et al; in press).20
Ultra-Performance Liquid Chromatography−Mass
Spectrometry
Detailed UPLC−MS protocols have been previously described
(Vorkas et al; in press).20 Brieﬂy, aqueous extracts were subjected
to hydrophilic interaction (liquid) chromatography (HILIC)
UPLC−MS analysis, whereas organic extracts were subjected
to a lipid proﬁling reversed-phase (RP) UPLC−MS analysis.
A quality control pooled sample (QC) was injected every
10 samples in order to assess instrument stability and feature
reproducibility through the run.21 Data extraction for both ana-
lyses was conducted using MarkerLynx XS (Waters Inc., v. 4.1)
software. Data extraction comprised peak picking and grouping
followed by total area normalization.
Statistical Analysis
Multivariate data analysis (MVDA) for UPLC−MS data was
conducted using SIMCA-P+ (v. 12.0.1.0; Umetrics). Principal
components analysis (PCA) and orthogonal projection to latent
structures-discriminant analysis (OPLS-DA) were applied to the
processed Pareto-scaled data. Model validation was carried out
using CV-ANOVA testing.22
Table 1. Patient Demographics of Carotid, Femoral, and Intimal Thickening Groups
carotida femorala intimal thickeninga
no. of samples 52 26 16
age, median (range) 69 (44−87) 74 (60−91) 69 (58−91)
gender, male (%) 40 (77) 17 (65) 13 (81)
statin therapy (%) 40 (82) {3} 19 (73) 13 (87) {1}
antiplatelet therapy (%) 43 (86) {3} 22 (85) 14 (93) {1}
hypertension (%) 32 (68) {5} 13 (50) 7 (47) {1}
diabetes mellitus (%) 11 (22) {3} 7 (27) 6 (40) {1}
ever smoker (%) 25 (52) {4} 18 (69) 11 (73) {1}
body mass index, median (range) 25.5 (17.4−41.2) {9} 23.0 (21.6−33.3) {13} 25.4 (21.0−47.7) {6}
a{ } indicates the number of missing patients.
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In order to extract putative biomarkers from the UPLC−MS
data, metabolite features with a correlation coeﬃcient (pcorr,
correlation coeﬃcient that refers to correlation of samples to
disease classes) greater than 0.5 in absolute value were chosen
(p < 0.001). These features were further subjected to two-tailed
t-test, assuming unequal variance with a threshold of p < 0.05,23,24
and fold-change comparison using their median values. Features
were reported as signiﬁcant and structurally identiﬁed if (1) both pcorr
and t-test p-value met the thresholds, (2) they were reproducible
through the run, with a coeﬃcient of variation (CV%) in the QC
samples of less than 30%, and (3) they passed the chromatographic
peak shape assessment. A brief ﬂowchart of the conditions that a
feature had to pass in order to be considered statistically signiﬁcant
and robust is illustrated in Supporting Information Figure S1.
Structural Assignment of Candidate Biomarkers
Elucidation and validation of the molecular structure of signi-
ﬁcant features is critical for the process of biological inter-
pretation. Here, we have used multiple methods to elucidate and
validate the molecular structures of candidate biomarkers.
Structural elucidation of signiﬁcant features was initially guided
by matching accurate m/z measurements to metabolites
from available online databases.25−27 The extraction phase (i.e.,
aqueous or organic) along with retention time also contributed
to narrowing putative matches. In some cases, isotopic patterns
and an in-house developed library were used to provide addi-
tional conﬁrmation.20,28 Furthermore, UPLC−MSE and UPLC−
MS/MS data were used for structural elucidation. For lipid proﬁling
analyses, MSE data were collected for every sample throughout the
run, whereas for the HILIC−UPLC−MS analyses, MSE data were
collected only on pooled samples (QCs) at the end of the run. The
conditions described for each run were identical to those used for
MS/MS analysis, either conducted using data-dependent acquis-
ition (DDA) or by targeting speciﬁc ions. MS/MS data were
collected with collision energy ramping from 30 to 50 eV for lipid
proﬁling and 20 to 40 eV for HILIC analysis. Supporting
Information Tables S1 and S2 present all of the features detected
with statistical signiﬁcance, and structurally assigned metabo-
lites were allocated a level of assignment, according to whether
they were matched to (1) accurate mass, (2) accurate mass and
tandemMS to in silico fragmentation pattern, (3) tandemMS from
databases or literature, (4) authentic standard matched to retention
time, and (5) authentic standard matched to MS/MS spectrum.
Unknown or tentative assignments are also stated.
Additional methods were further employed in order to vali-
date elucidated molecular structures, providing an extra level
of conﬁdence. These methods proved useful for revealing
biological associations between metabolites using pathway
mapping and mathematical pairwise correlations (r). The
detailed methodological procedures are described in the
following paragraphs.
Analytical Standards
Standards were of analytical grade with typical purity >99%. A
detailed description is presented in the Supporting Information.
Correlation Network Analysis
Spearman pairwise correlation coeﬃcients (r) between pairs of
metabolites (detected as being diﬀerent between the groups with
statistical signiﬁcance), along with two-tailed signiﬁcance tests
(p-value), were calculated using R (2.13.2) programming
language. When a metabolite was detected as being statistically
diﬀerent using more than one method or polarity mode, the
condition under which the metabolite demonstrated the lowest
Figure 1. Scores plots of principal components analysis (PCA) of the
tissue extracts (blue, intimal thickening tissue; red, carotid plaques;
yellow, femoral plaques). (A) Positive mode (ESI+) lipid proﬁling using
reversed-phase ultra-performance liquid chromatography coupled to
mass spectrometry (RP−UPLC−MS); (B) negative mode (ESI−) lipid
proﬁling using RP−UPLC−MS; (C) positive mode (ESI+) analysis of
aqueous extracts using hydrophilic interaction ultra-performance liquid
chromatography coupled to mass spectrometry (HILIC−UPLC−MS)
analysis; (D) negative mode (ESI−) analysis of aqueous extracts using
HILIC−UPLC−MS analysis.
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CV%was preferred for representation. For network visualization,
CytoScape (v.3.0.0-beta1) software was used.
Metabolite Mapping
Metabolite mapping was conducted using the KEGG database.29
A number of metabolites were also mapped based on literature
ﬁndings.
Venn Diagrams
Venn diagrams of detected metabolites per method and
polarity mode were constructed using online available software
(http://bioinfogp.cnb.csic.es/tools/venny/).
■ RESULTS AND DISCUSSION
Metabolic Proﬁling Reveals the Metabotype of the
Lipid-Laden Plaque
Complex diseases such as atherosclerosis with mosaic etiological
factors necessitate a systemic approach for their mechanistic
understanding and for optimization of therapeutic targets.
Advances in UPLC−MS technology,30 resulting in the ability
to proﬁle thousands of metabolites reliably in biological
matrices, present opportunities for continuous discovery.
This can be the case even in a widely studied disease such as
atherosclerosis. We applied two UPLC−MS methodologies,
covering a range of metabolites with substantial diversity of
physicochemical properties, to characterize metabolic alterations
from the intimal thickening stage to the lipid-laden stenosing
plaque.
The metabotype of atherogenesis could function as a meta-
bolic atlas to guide future studies on atherosclerosis. In order to
accomplish this, we ﬁrst applied principal components analysis
(PCA) to map the UPLC−MS proﬁles (Figure 1). We observed
a clear separation between samples from INT and plaque
lesions from the CAR and FEM locations. This indicated
distinct metabotypes of human INT and advanced plaque
lesions. The samples from CAR and FEM tissue also formed
distinct groups, with the CAR phenotype being metabolically
closer to INT rather than the FEM plaque tissue. Conversely,
INT tissue, although collected from the carotid and femoral
arterial bifurcations, did not present metabolic origin-related
diﬀerences.
We further applied orthogonal projection to latent structure-
discriminant analysis (OPLS-DA) in order to optimally extract
candidate metabolites responsible for diﬀerentiating between
the intimal thickening tissue and the two atherosclerotic plaque
groups. OPLS-DA was performed in a pairwise fashion, wherein
CAR and FEM were compared individually with the INT tissue
group. Both models displayed high predictive values, indicating
distinctive metabotypes for INT versus plaque tissue; model
diagnostics indicated that the models were robust and predictive
(Table 2). Cross-validation ANOVA testing (CV-ANOVA) was
applied as a signiﬁcance test of the OPLS models (Table 2).22
Cross-validated scores plots of the analyzed samples are shown
in Supporting Information Figure S2.
The constructed multivariate models, in conjunction with
univariate statistical analysis, enabled highly signiﬁcant features
to be revealed. We assigned >150 unique metabolite structural
identities for features that were found to be statistically signiﬁcant
in diﬀerentiating between tissue groups (Figures 2 and 3 and
Supporting Information Tables S1 and S2). Lipid moieties clas-
siﬁed into 5 diﬀerent lipid classes and 17 subclasses, according to
the proposed classiﬁcation system,31 were structurally assigned.
A large number of the metabolites were identiﬁed as being
statistically signiﬁcant in more than one UPLC−MS analysis or
polarity mode.
The common metabolites detected with statistical signiﬁcance
in both CAR and FEM (Figure 4) after individual comparisons to
controls follow the same trends in both disease locations. This
common signature of perturbed metabolites can provide a good
overview of the basis of metabolic dysregulation leading to
plaque formation and will be the main focus of analysis and
discussion in the following paragraphs. Several metabolites
demonstrated statistical signiﬁcance with only one of the tested
plaque locations. However, a detailed comparison between the
plaque tissues from the two anatomical locations goes beyond
the scope of this article.
Higher Levels of Free Cholesterol and Cholesterol
Derivatives in Plaques Provide Conﬁdence in Our
Experimental Design
Free cholesterol (Cho) and cholesterol derivatives are well-
established risk factors for atherogenesis.32 Accumulation of
cholesteryl esters (CE) is considered to be a major contributor to
plaque formation, whereas Cho accumulates in advanced
atherosclerotic plaques.33 In this study, we detected Cho with
higher intensities in both CAR and FEM tissue as compared
to that in INT (Figures 4D and 5A,B). Moreover, several
oxidized cholesteryl ester (oxCE) moieties were detected
with higher intensities in plaques, with higher statistical
signiﬁcance and fold-change than that of Cho. Additional
involvement of the Cho pathway is shown in FEM, where
cholesterol sulfate was also found to be higher by 2-fold
compared with INT samples. Although the detection of higher
levels of Cho and derivatives does not constitute a novel
ﬁnding, it does provide further validation of our experimental
design and ﬁndings.
Table 2. Summary of Model Characteristics from OPLS-DA Multivariate Statistical Analyses of Data Obtained from All Analyses
and Electrospray Ionization Polarity Modesa
groups analysis polarity mode components (pred + orthog) R2X R2Y Q2Y CV-ANOVA
CAR vs INT LP Pos 1 + 1 0.280 0.609 0.432 1.02 × 10−6
Neg 1 + 2 0.412 0.786 0.502 3.99 × 10−7
HL Pos 1 + 0 0.131 0.496 0.356 1.48 × 10−6
Neg 1 + 1 0.215 0.721 0.467 2.31 × 10−7
FEM vs INT LP Pos 1 + 1 0.423 0.861 0.755 2.82 × 10−10
Neg 1 + 1 0.383 0.834 0.746 5.52 × 10−10
HL Pos 1 + 1 0.209 0.895 0.703 4.54 × 10−9
Neg 1 + 0 0.193 0.846 0.797 1.59 × 10−13
aCAR, carotid plaque arterial tissue; FEM, femoral plaque arterial tissue; INT, intimal thickening arterial tissue; LP, lipid proﬁling; HL, HILIC
analysis of aqueous extracts; Pos, positive polarity mode; Neg, negative polarity mode; pred, predictive components; orthog, orthogonal component;
CV-ANOVA, cross-validation ANOVA testing of residual values from cross-validation testing.
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Figure 2. Statistically signiﬁcant metabolite changes between carotid plaques and intimal thickening tissue. Bar plots represent, from left to right,
−log(p-value) of t-test (two-tailed; assuming unequal variance), pcorr obtained from orthogonal projection to latent structures-discriminant analysis
(OPLS-DA), and fold change.
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Figure 3. Statistically signiﬁcant metabolite changes between femoral plaques and intimal thickening tissue. Bar plots represent, from left to right,
−log(p-value) of t-test (two-tailed; assuming unequal variance), pcorr obtained from orthogonal projection to latent structures-discriminant analysis
(OPLS-DA), and fold change.
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All oxCEs detected in higher levels were esteriﬁed exclusively
with 18C fatty acyl chains; these chains were detected with
incorporating 1−3 oxygen atoms. Free radicals have been sug-
gested to promote the production of oxCE.34,35 Lipid oxidation is
known to be caused by reactive oxygen species (ROS) and aﬀects
unsaturated fatty acids as well as cholesteryl esters and Cho
itself.35 Lipid oxidation can ultimately result in an oxidation chain
reaction and cell membrane damage34 and has a well-recognized
role in the progression of atherogenesis.33 Moreover, oxCEs are
known to contribute to foam cell formation,36 since macrophages
are less eﬃcient for oxCE degradation.37 The structures of
oxCE moieties identiﬁed in this study are in concordance with
published literature.38
Dysregulation of Purine and Pyrimidine Pathways
UsingHILIC analysis, we observed a large number of metabolites
from the purine and pyrimidine pathways detected in lower
intensities in both plaque groups. These include inosine
(Figure 4D), uridine, hypoxanthine, guanosine, and methylur-
idine (Figures 2 and 3 and Supporting Information Tables S1 and
S2). These results provide additional validity to the current
study, since they are well-established for their involvement in
atherosclerosis.39,40 Triphosphates of adenosine and uridine are
released from endothelial cells in response to sheer stress.41
Purines and pyrimidines control vascular tone40,41 in a process
related to hypoxia, and a number of them, such as adenosine
and inosine, are known for their anti-inﬂammatory eﬀects.42,43
Purines and pyrimidines are essential for cell proliferation,44 and
their inhibition can lead to apoptosis.44 Metabolites of these
pathways are components or precursors of RNA and DNA.
The Ceramide Pathway Suﬀers Extensive Homeostatic Loss
in Plaque Tissue
Dysregulation of the Cer pathway was detected with several
altered metabolites (Supporting Information Figure S3). This was
evident by the global reduction in the levels of a number of
sphingomyelin (SM) moieties, which, together with the detected
higher levels of ceramides (Cer) (Figures 2 and 3) in the diseased
groups, indicated involvement of the sphingomyelinase (SMase)
enzyme. SMase catalyzes the production of Cer by hydrolysis of
the phosphoesteric bond of the phosphocholine headgroup of
SMs and has been previously shown to be involved in athero-
sclerosis.45 The Cer pathway is known for its involvement in
atherosclerosis,46 with a role in apoptosis,47 and connections to
pro-inﬂammatory factors, ROS and nitric oxide.46
We also found that glycosphingolipids, another sphingolipid
subclass, were dysregulated. Studies detecting glycosphingolipid
involvement in atherogenesis have existed in the literature for
40 years.48 They have been implicated as signaling molecules in
vascular cell proliferation under oxidative conditions45 as well as
for platelet activation and adhesion to the vessel wall.49 In the
present study, tetrahexosylceramide (tetraHexCer) (Figure 4D)
Figure 4. Analysis of metabolites found to be commonly dysregulated with statistical signiﬁcance after separate comparisons of carotid (CAR) and
femoral (FEM) plaques to intimal thickening tissue (INT). (A) Venn diagram demonstrating the number of unique and commonly dysregulated
metabolites between the two anatomical locations. These metabolite entities were deemed to be signiﬁcant after individual comparisons to INT. (B)
Correlation matrix of metabolite pairs using Spearman correlation. (C) Correlation network of metabolite pairs found to have a Spearman correlation of
absolute value ≥ 0.65. (D) Box plots of highlighted metabolites from the correlation network. These metabolites are considered to be important due to
the central role (hubs) in the network or prior knowledge of importance in the disease studied according to the literature.
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and trihexosylceramide (triHexCer) were detected in lower
intensities in plaques and in the form of d18:1/16:0. Speciﬁcally,
tetraHexCer was detected with strong statistical signiﬁcance in
both disease locations (Figures 2, 3, and 5A,B).
Phosphatidylethanolamine-Ceramides: New Candidate
Biomarkers in Atherogenesis
Phosphatidylethanolamine-ceramides (PE-Cer) are also mem-
bers of the Cer pathway. To our knowledge, PE-Cers have
neither been previously investigated in the context of
atherosclerotic plaque formation nor directly related to any
other human disease. In this study, using well-validated
multivariate models, the levels of two PE-Cers were detec-
ted to be highly correlated to the plaque groups (|pcorr| =
0.70−0.94) (Figures 2, 3, and 5C,D) and with t-test p-values
3.8 × 10−6 to 9.8 × 10−12 (Figures 2 and 3). The structures of
the two detected PE-Cers were elucidated using MS/MS
experiments and were identiﬁed as PE-Cer(d18:1/16:0) and
PE-Cer(d18:1/24:1). MS/MS spectra used for structural
elucidation along with parent and fragment ion structures
are presented in Supporting Information Figure S4.
PE-Cer involvement in the progression of plaque formation
was evident in plaques from both anatomical locations (CAR and
FEM), indicating a common basis for disease progression
(Figure 4D). PE-Cers are found only in trace concentrations in
mammalian cells.50 A selective synthase, namely, sphingomyeli-
nase synthase-related (SMSr),51 also referred to as sterile alpha
motif domain containing 8 (SAMD8) or CDP-ethanolamine:N-
acylsphingosine ethanolaminephosphotransferase,29 is responsible
for PE-Cer synthesis by transferring the phosphoethanolamine
group from phospatidylethanolamines (PE) to Cers.29 This
enzyme has been reported to be essential to ceramide homeostasis
in experiments conducted in human cells.51
The inverse correlation (Figure 4B,C) of PE-Cer to Cer is
in concordance with the aforementioned biochemical reaction
(Supporting Information Figure S3). However, PEs did not share
the same trend as Cer. On the contrary, PEs had a high positive
correlation to PE-Cers. PE-Cers also showed high correlations with
members of the purine and pyrimidine pathways, namely, inosine,
uridine, guanosine, hypoxanthine, andmethyluridine (Figure 4B,C).
Speciﬁcally, whenmetabolites commonly dysregulated in bothCAR
and FEM were assembled in a correlation network (Figure 4C),
inosine (Figure 4D)was themetabolite demonstrating a central role
(hub) in the network and connecting PE-Cer(d18:1/16:0) and
tetraHexCer(d18:1/16:0), both metabolites of the Cer pathway,
with PEs, oxCE, and pyrimidine and purine pathways.
High observed correlations between PE-Cers and other
members of the ceramide pathway are to be expected. However,
correlations of PE-Cers to tetraHexCer were generally higher
than triHexCer and at the same level as with Cers. This should be
further explored since it is not consistent with canonical path-
ways (Supporting Information Figure S3), but it is indicative of a
more direct association between PE-Cers and tetraHexCers.
Phosphatidylethanolamine-Ceramides Link the Ceramide
Pathway to Free Cholesterol
Eﬀorts have previously been made to connect the Cer pathway
to Cho,52,53 since some degree of association has been shown
Figure 5. S-plots obtained from orthogonal projection to latent structures-discriminant analysis (OPLS-DA) of the data obtained from the organic tissue
extracts. Plots highlight statistically and/or biologically signiﬁcant metabolites. (A) Positive mode (ESI+) lipid proﬁling using reversed-phase ultra-
performance liquid chromatography coupled to mass spectrometry (RP-UPLC-MS) of the comparison between carotid plaque tissue (CAR) organic
extracts and intimal thickening (INT). (B) Positive mode lipid proﬁling using RP-UPLC-MS of the comparison between femoral plaque tissue (FEM)
organic extracts and INT. (C) Negative mode (ESI−) lipid proﬁling using RP-UPLC-MS of the comparison between CAR organic extracts and INT.
(D) Negative mode lipid proﬁling using RP-UPLC-MS of the comparison between FEM organic extracts and INT.
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between them,54 particularly with respect to their proposed
involvement in atherosclerosis.46 Here, we identiﬁed strong
inverse pairwise correlations of PE-Cers to Cho, the highest
found correlations to Cho of any metabolite detected with
statistical signiﬁcance. Figure 3B,C and Supporting Information
Figure S5 illustrate this high correlation of Cho to PE-
Cer(d18:1/16:0) (r = −0.76; p = 2.9 × 10−18) and PE-
Cer(d18:1/24:1) (r = −0.61; p = 2.2 × 10−10). The remaining
detected Cer pathway metabolites showed |r| < 0.50, consis-
tent with a less direct association. Therefore, PE-Cers, and
predominantly PE-Cer(d18:1/16:0), have potential to be the
missing link from the association of Cho to the Cer pathway.
Macrophage apoptosis is an established feature of athero-
genesis,55 and Cho has been previously shown to have the ability
to induce apoptosis in macrophages.56 Additionally, it has been
recently shown that the SMSr enzyme functions as a suppressor
of ceramide-induced mitochondrial apoptosis.57 We therefore
propose that Cho promotes apoptosis through reduction of
the activity of the SMSr enzyme. Nonetheless, the association
between PE-Cers and Cho may be of translational potential in
the context of targeting the PE-Cer reaction in order to reduce
the lipid load within the atherosclerotic plaque as well as for use
as a diagnostic marker of active and advancing atherogenesis.
Truncation of β-Oxidation andConsumption of Unsaturated
Lipids Suggests Dysregulation of Metabolic Oxidation
Global perturbations of acylcarnitine (AcC; carnitine ester)
metabolism was manifested in plaque tissue. Speciﬁcally, we
observed that, while levels of short-chain AcCs were detected
with fold changes as low as−2.2 in CAR and FEM, medium- and
long- (≤16C) chain AcC levels were increased in CAR and FEM,
respectively (Figures 2 and 3). AcCs are involved in the translo-
cation of fatty acyl chains through the mitochondrial membrane.
Our ﬁndings implicate mitochondrial metabolism, speciﬁcally,
β-oxidation, in plaque development. We also observed a reduc-
tion in lipid species with highly unsaturated FACs in plaque
tissue (Figures 2−4). The accumulation of medium- and long-
chain AcCs led us to hypothesize that β-oxidation is truncated,
consequently reducing the production of short-chain AcCs and
leading to the recruitment of unsaturated FACs in order to
compensate metabolic requirements. These ﬁndings are indi-
cative of dysregulations in metabolic oxidation.58 It is known that
β-oxidation and oxidative conditions, in general, are linked to
inﬂammation.59 Additionally, the aforementioned mitochondrial
apoptosis has been previously associated with reduction of
β-oxidation.60 Oxidative stress and mitochondrial dysfunction
are known to be involved in the manifestation of atheroscle-
rosis.61,62
■ CONCLUSIONS
Atherosclerosis is a systemic, multicentric, and multistage disease
and should be put into context as such. In this study, we ﬁrst
present the metabotype of atherogenesis, providing more
than 150 assigned metabolites. Dysregulated metabolites were
identiﬁed using a diagnostic combination of multivariate and
univariate statistics. We further highlight new biochemical path-
ways suggested as being involved in metabolic perturbations
responsible for the progression from intimal thickening to
stenosing atherosclerotic plaque. The choice of intimal thickening
tissue as the control group, along with metabolites detected with
trends in concordance with the published literature and well-
established risk factors, namely, Cho and oxCEs,32,38 purines and
pyrimidines, and the Cer pathways, provide additional conﬁdence
in our ﬁndings.
We observed interruption of β-oxidation in atherosclerotic
plaque tissue, as inferred by the diﬀerential intensities of
acylcarnitines, along with the global recruitment of highly
unsaturated fatty acids and formation of oxCEs. Additionally, we
identiﬁed a novel candidate biomarker in atherogenesis, namely,
phosphatidylethanolamine-ceramide, which demonstrated high
statistical association with cholesterol. These ﬁndings support
the identiﬁcation of novel potential pharmaceutical targets,
aiming toward reducing the plaque lipid load, a current and
unmet need of the medical community. Additionally, molecules
manifesting altered levels could function as indicators of current
and profound atherogenesis with potential applications in
guiding treatment. Taken together, our ﬁndings convey the
systemic metabolic signature of atherosclerotic plaque formation,
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